GlycoMimetics To Present Interim Analysis Of Phase 1b Proof-Of-Concept Study At American Association For Cancer Research Apr. 10, 2021
GlycoMimetics To Present Interim Analysis Of Phase 1b Proof-Of-Concept Study At American Association For Cancer Research Apr. 10, 2021
GlycoMimetics, Inc. (NASDAQ:GLYC) today announces that an abstract presenting the interim analysis of a Phase 1b proof-of-concept study of GMI-1359, the Company’s dual antagonist of E-selectin and CXCR4, has been accepted for presentation at the American Association of Cancer Research (AACR) 2021 Annual Meeting, to be held virtually on April 10-15 and May 17-21. Preclinical studies indicate that targeting both E-selectin and CXCR4, a chemokine receptor, with a single compound could improve efficacy in the treatment of cancers that affect the bone and bone marrow, such as breast and prostate cancer. A second abstract also accepted for presentation highlights, for the first time, preclinical data in pancreatic cancer for the Company’s novel dual antagonist of galectin-3 and E-selectin, GMI-1757. The latter is featured as a late-breaking abstract on the compound’s impact on fibrosis, mononuclear cell infiltration, and anti-PD-L1 therapeutic activity in a pancreatic adenocarcinoma model.
GlycoMimtics，Inc.(納斯達克：甘露糖)今天宣佈，一份介紹該公司E-選擇素和CXCR4雙重拮抗劑GMI-1359 1b期概念驗證研究中期分析的摘要已被接受，將在4月10日至15日和5月17日至21日舉行的美國癌症研究協會(AACR)2021年年會上提交。臨牀前研究表明，用一種化合物同時針對E-選擇素和趨化因子受體CXCR4，可以提高治療影響骨骼和骨髓的癌症的療效，如乳腺癌和前列腺癌。第二份摘要也被接受為報告，第一次強調了該公司新的Galectin-3和E-選擇素雙重拮抗劑GMI-1757在胰腺癌的臨牀前數據。後者是關於該化合物在胰腺癌模型中對纖維化、單核細胞浸潤和抗PD-L1治療活性的影響的最新摘要。
GlycoMimetics Chief Executive Officer Rachel King said, “We look forward to sharing results from two programs in our advancing portfolio at the upcoming AACR meeting, including the interim analysis of Phase 1b clinical data supporting further advancement of the GMI-1359 program. We are extremely proud to be collaborating with the Duke Cancer Institute on this important work, which we believe holds great promise in delivering a novel approach to treating cancers with bone involvement.”
GlycoMimtics首席執行官雷切爾·金説：“我們期待着在即將到來的AACR會議上分享我們正在推進的產品組合中的兩個項目的結果，包括對支持GMI-1359項目進一步推進的1b期臨牀數據的中期分析。我們非常自豪能與杜克癌症研究所在這項重要工作上進行合作，我們相信這項工作在提供一種治療涉及骨骼的癌症的新方法方面大有希望。“
Details on GlycoMimetics e-presentations at the AACR Meeting are as follows:
GlycoMimtics在AACR會議上的電子演講詳情如下：
Title: “Development of GMI-1359, a Novel Agent Targeting Tumor-microenvironment Cross-talk in Bone Metastatic Breast Cancer”
Presenter: Dorothy Sipkins, M.D., Ph.D., Duke Cancer Institute
Session: e-Presentation
Date and Time: Saturday, April 10, 2021 (available online through Monday, June 21)
標題：骨轉移性乳腺癌腫瘤-微環境交互作用新葯GMI-1359的研製主講人：多蘿西·西普金斯(Dorothy Sipkins)，醫學博士，杜克癌症研究所(Duke Cancer Institute)博士會話：電子演示文稿日期和時間：2021年4月10日(星期六)(網上發售至6月21日(星期一))
Title: A novel glycomimetic compound (GMI-1757) with dual functional antagonism to E-selectin and galectin-3 attenuates fibrosis, facilitates mononuclear cell infiltration and optimizes anti-PD-L1 therapeutic activity in a pancreatic adenocarcinoma model
Presenter: William E. Fogler, M.D., GlycoMimetics
Session: e-Presentation
Date and Time: Saturday, April 10, 2021 (available online through Monday, June 21)
標題：一種對E-選擇素和Galectin-3具有雙重功能拮抗作用的擬糖化合物(GMI-1757)在胰腺癌模型中減輕纖維化，促進單個核細胞浸潤，優化抗PD-L1治療活性主講人：威廉·E·福格勒(William E.Fogler)，醫學博士，糖仿生學會話：電子演示文稿日期和時間：2021年4月10日(星期六)(網上發售至6月21日(星期一))
譯文內容由第三人軟體翻譯。